Lead Product(s): Pindolol
Therapeutic Area: Oncology Product Name: ACM-001
Highest Development Status: Phase II Product Type: Small molecule
Deal Size: $3.4 million Upfront Cash: Undisclosed
Deal Type: Series B Financing June 10, 2021
The proceeds will allow Actimed to further advance the development of its lead compound, S-pindolol (ACM-001.1), for cancer cachexia, by performing a Pharmacokinetic (PK) and Pharmacodynamic (PD) study due to start later this year.